NorthStar Medical Radioisotopes and Curadh MTR Announce a Strategic Long Term Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)
NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals, and Curadh MTR Inc. (Curadh), a global MTR focused clinical, research and advisory organization, today announced the signing of a strategic long term supply agreement for the therapeutic radioisotope non-carrier added (n.c.a.)
- NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals, and Curadh MTR Inc. (Curadh), a global MTR focused clinical, research and advisory organization, today announced the signing of a strategic long term supply agreement for the therapeutic radioisotope non-carrier added (n.c.a.)
- View the full release here: https://www.businesswire.com/news/home/20230829331776/en/
Under the terms of the agreement, NorthStar will supply its high purity, n.c.a. - Ac-225 to Curadh for use in its pioneering molecularly targeted radiation (MTR) programs for the treatment of common lethal tumors.
- Ac-225 with Curadh,” said Frank Scholz, Ph.D., President and Chief Executive Officer of NorthStar Medical Radioisotopes.